source
- AstraZeneca's breast cancer drug camizestrant fails pivotal first-line trialAstraZeneca announced that its investigational breast cancer drug camizestrant did not meet primary endpoints in a pivotal Phase 3 trial evaluating it as a first-line treatment for advanced disease…
- Definium’s LSD therapy cuts anxiety scores in second late-stage trialDefinium Therapeutics reported that its LSD-based drug DT120 reduced anxiety symptoms in a second late-stage study. In the 12-week trial, patients receiving a 100-microgram dose saw an average 9.8…